Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 16/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 12/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 6/20 | 0.41 |
| ▸ | MAOA | P21397 | 6/20 | 0.41 |
| ▸ | MAOB | P27338 | 6/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21169469 | 1.00 | MEN1 (0.43) | MEN1KMT2AP2RY12KDM1AMAOA | |
| SCHEMBL19992126 | 1.00 | MEN1 (0.43) | MEN1KMT2AP2RY12KDM1AMAOA | |
| SCHEMBL19979444 | 0.89 | P2RY12 (0.51) | MEN1KMT2AP2RY12KDM1AMAOA | |
| SCHEMBL19992122 | 0.89 | MEN1 (0.49) | MEN1KMT2AP2RY12KDM1AMAOA | |
| SCHEMBL21169531 | 0.89 | MEN1 (0.49) | MEN1KMT2AP2RY12KDM1AMAOA | |
| SCHEMBL19992121 | 0.89 | MEN1 (0.49) | MEN1KMT2AP2RY12KDM1AMAOA | |
| SCHEMBL21169624 | 0.88 | MEN1 (0.50) | MEN1KMT2AP2RY12KDM1AMAOA | |
| SCHEMBL21169534 | 0.88 | MEN1 (0.50) | MEN1KMT2AP2RY12KDM1AMAOA | |
| SCHEMBL21160534 | 0.87 | MEN1 (0.54) | MEN1KMT2AP2RY12KDM1AMAOA | |
| SCHEMBL19992246 | 0.85 | MEN1 (0.50) | MEN1KMT2AP2RY12KDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975100-B2 | Fused bicyclic inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-13 | — | — | US | disclosed |
| US-20200172556-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
| US-10611778-B2 | Fused bicyclic inhibitors of menin-MLL interaction | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-07 | — | — | US | disclosed |
| US-20190218230-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | Janssen Pharmaceultica nv (BE) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218230-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, BMI1, MEN1 | MEN1 3/4885KMT2A 81/4885P2RY12 4690/4885 |
| US-10611778-B2 | Fused bicyclic inhibitors of menin-MLL interaction | MLLT1, BMI1, MEN1 | MEN1 3/4885KMT2A 81/4885P2RY12 4690/4885 |
| US-20200172556-A1 | FUSED BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, BMI1, MEN1 | MEN1 3/4885KMT2A 81/4885P2RY12 4690/4885 |
| US-10975100-B2 | Fused bicyclic inhibitors of menin-MLL interaction | MLLT1, BMI1, MEN1 | MEN1 3/4885KMT2A 81/4885P2RY12 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.